-
-
-
-
-
-
-
Palatin Technologies (PTN) reported Q1 result
-
-
-
-
-
-
-
Palatin Technologies (PTN) Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
-
-
-
-
-
-
-
Palatin Technologies' (PTN) PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Palatin Technologies (PTN)
-
-
-
-
-
-
-
Palatin Technologies (PTN) Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
-
-
-
-
-
452,629 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

